

1 A Scintillator-based Approach to Monitor Secondary Neutron Production
2 During Proton Therapy

3
4 S. D. Clarke¹, E. Pryser¹, B. M. Wieger¹, S. A. Pozzi¹, R. A. Haelg², V. A. Bashkirov³,
5 R. W. Schulte³

6
7 ¹Department of Nuclear Engineering and Radiological Sciences
8 University of Michigan
9 2355 Bonisteel Blvd.
10 Ann Arbor, MI 48109, USA

11
12 ²Center for Proton Therapy
13 Paul Scherrer Institut
14 5232 Villigen PSI West, Switzerland
15

16 ³Division of Radiation Research, Dept. of Basic Sciences
17 Loma Linda University
18 11021 Campus St.
19 Loma Linda, CA, USA
20

21 PURPOSE – The primary objective of this work is to measure the secondary neutron field produced
22 by an uncollimated proton pencil beam impinging on different tissue equivalent phantom
23 materials using organic scintillation detectors. Additionally, the Monte Carlo code MCNPX-
24 PoliMi was used to simulate the detector response for comparison to the measured data.
25 Comparison of the measured and simulated data will validate this approach for monitoring
26 secondary neutron dose during proton therapy.

27

28 METHODS – Proton beams of 155- and 200-MeV were used to irradiate a variety of phantom
29 materials and secondary particles were detected using organic liquid scintillators. These
30 detectors are sensitive to fast neutrons and gamma rays: pulse shape discrimination was used to
31 classify each detected pulse as either a neutron or a gamma ray. The MCNPX-PoliMi code was
32 used to simulate the secondary neutron field produced during proton irradiation of the same
33 tissue equivalent phantom materials.

34

35 RESULTS – An experiment was performed at the Loma Linda University Medical Center proton
36 therapy research beam line and corresponding models were created using the MCNPX-PoliMi
37 code. Our analysis showed agreement between the simulations and the measurements. The
38 simulated detector response can be used to validate the simulations of neutron and gamma
39 doses on a particular beam line with or without a phantom.

40

41 CONCLUSIONS – We have demonstrated a method of monitoring the neutron component of the
42 secondary radiation field produced by therapeutic protons. The method relies on direct
43 detection of secondary neutrons and gamma rays using organic scintillation detectors. These
44 detectors are sensitive over the full range of biologically relevant neutron energies above 0.5
45 MeV and allow effective discrimination between neutron and photon dose. Because the detector
46 system is portable, the described system could be used in the future to evaluate secondary
47 neutron and gamma doses on various clinical beam lines for commissioning and prospective
48 data collection in pediatric patients treated with proton therapy.

49 ABSTRACT – Proton therapy facilities use 70 – 250 MeV proton beams to destroy cancerous cells.
50 In this approach, secondary radiation is produced due to proton interactions with the patient,
51 and the beam-line components. This secondary radiation field, which includes both neutrons and
52 photons, must be accurately characterized in order to determine its effect on patients and
53 medical personnel. Experiments were performed at the Loma Linda University Medical Center
54 proton therapy research beam line in order to validate the Monte Carlo models. Proton beams
55 of 155- and 200-MeV were used to irradiate a variety of phantom materials and secondary
56 particles were detected using organic liquid scintillators. These detectors are sensitive to fast
57 neutrons and gamma rays: pulse shape discrimination was used to classify each detected pulse
58 as either a neutron or a gamma ray. The MCNPX-PoliMi code was used to simulate the secondary
59 neutron field produced during proton irradiation of the same tissue equivalent phantom
60 materials. Data analysis showed good agreement between the simulations and the
61 measurements. The measurement system demonstrated here can be used to monitor secondary
62 radiation fields produced during proton therapy, and for prospective data collection and second
63 cancer risk estimations.

64

65 1. INTRODUCTION

66 Proton therapy facilities use high-energy protons in place of the more traditional photons or
67 electrons to treat cancer. Protons are recognized for highly conformal dose distributions that
68 improve local tumor control while reducing normal tissue toxicity by limiting unwanted dose. In
69 theory, patients treated with protons should have a drastically lowered risk for radiation-induced
70 secondary malignancies. However, there is concern that high-energy neutrons produced from
71 the inelastic scattering of protons within the treatment head and within the patient may reduce
72 this benefit by depositing unwanted dose outside of the target volume.

73 Because young patients are more sensitive to radiation, and thus more likely to develop
74 secondary malignancies upon radiation exposure [1], proton therapy has been considered
75 superior to photon therapy in the treatment of pediatric patients. The reduced dose to normal
76 tissue offered by protons would, in theory, reduce the number of secondary cancers seen in
77 pediatric patients. However, the presence of the secondary radiation field, mostly due to
78 secondary neutrons and gamma rays, suggests that there may be an additional small risk of
79 secondary cancers that needs to be considered. Additionally, a case study performed by Dorr
80 and colleagues determined that 50% of second malignancies occurred within a 5 cm margin
81 surrounding the treatment field, while less than 10% of secondary malignancies occurred inside
82 of the field [2]. Hence, it will be critical to evaluate the benefits of proton therapy, specifically for
83 pediatric cases, with carefully designed prospective studies that include evaluation of the
84 secondary radiation field. Because of their relatively high biological impact, the neutron
85 component of the field is of particular interest.

86 Rem-meters, often based on neutron moderation, generally have low sensitivity to neutrons
87 with energies greater than 15 MeV [3]. Additionally, even advanced neutron dosimeters
88 underestimate doses from neutrons less than 2 MeV [4]. Because the biological effectiveness of
89 neutrons is strongly dependent on their energy, and because the energy spectrum of secondary
90 neutrons extends to the energy of the incident proton beam, rem-meters are inadequate for
91 neutron monitoring purposes in this environment. Accurate neutron monitoring in a proton
92 therapy facility necessitates a detector that can perform active, fast neutron spectroscopy up to
93 energies of 250 MeV and can discriminate between their neutrons and associated gamma rays.
94 Furthermore, the detectors used in this work are sensitive to both neutrons and gamma rays,
95 which can enable monitoring of the dose from the complete secondary radiation field.

96 From the patient perspective, the neutron dose deposited in normal tissues is of primary
97 importance. This dose is primarily from external neutrons produced in the treatment head as well
98 as internal neutrons produced in the patient. In practice, secondary dose evaluation inside the
99 patient is best done with a Monte Carlo simulation combined with a digital phantom used as a
100 patient surrogate. Modern hybrid phantoms [5] can be deformed to create an age- and weight-
101 adjusted model of a specific patient that is matched to the partial patient anatomy known from

102 a planning CT scan of the patient. Previous studies of secondary neutron doses have been
103 performed with the Geant4 Monte Carlo code [6, 7] or the Monte Carlo code MCNPX [8, 9]. It is
104 important that correct implementation of these codes is validated with experimental studies on
105 clinical proton beam lines.

106 The primary objective of this work is to measure the secondary neutron field produced by an
107 uncollimated proton pencil beam impinging on different tissue equivalent phantom materials
108 using organic scintillation detectors. Additionally, the Monte Carlo code MCNPX-PoliMi was
109 used to simulate the detector response for comparison to the measured data. Comparison of
110 the measured and simulated data was performed to validate this approach for monitoring
111 secondary neutron dose during proton therapy.

112


113 2. DESCRIPTION OF THE EXPERIMENT

114 An experiment was performed at the Loma Linda University Medical Center proton therapy
115 research beam line. Pulsed proton beams with a cycle time of about 2 seconds and an active
116 spill length between 0.3 and 0.5 seconds were used to irradiate a variety of radiation therapy
117 phantoms at energies of 155 and 200 MeV; the beam diameter was 2 cm at the exit of the
118 vacuum tube and approximately 4 cm at the entrance of the phantom blocks. The beam current
119 monitor in the research beamline was not operational and no ion chamber was available, so the
120 total dose delivered to the blocks is unknown. The secondary particles were detected using two
121 3-inch diameter by 3-inch thick EJ-309 organic liquid scintillators [10]. These detectors are each
122 sensitive to fast neutrons and gamma rays. The signal from each detector is independently
123 collected with a fast photomultiplier tube, with a time resolution of approximately 1.0 ns. Pulse
124 shape discrimination (PSD) was used to classify each detected pulse as either a neutron or a
125 gamma ray, which allows selective analysis of the incident energy spectra. The PSD algorithm
126 relies on integration of the individual pulses from the detectors; the integration range used for
127 PSD determines the effective deadtime of the cells, in this case approximately 300 ns.

128 Four tissue-equivalent phantom materials manufactured by Computerized Imaging
129 Reference Systems (CIRS), Inc., Norfolk, VA were irradiated: compact bone, soft tissue, plastic
130 water and trabecular bone. Each of the phantoms were 30 cm by 30 cm in the transverse
131 dimension; the thickness varied from 18 cm to 30 cm, but in each experiment was thick enough
132 to completely stop the proton beam. The proton beams were aligned 5 cm from the detector-
133 facing edge of the phantom being irradiated. Irradiations were performed for 20 min with 200-
134 MeV beam and 30 min with the 155-MeV beam. Data were acquired using a digital measurement
135 system developed by the University of Michigan Detection for Nuclear Nonproliferation Group
136 based on a CAEN DT5720 waveform digitizer (12 bit, 250 MHz). Fig. 1 shows a photograph of
137 the experimental setup; the beam direction is left-to-right. The detectors were located 70 cm
138 from the target perpendicular to the beam line.

139 The two detectors were gain-matched using a ^{137}Cs source, aligning the Compton edge to
140 300 mV. A detection threshold of 80 keV-electron-equivalent (keVee) was applied, which is
141 defined as the amount of scintillation light that is emitted when a photon deposits 80 keV on an
142 electron in the scintillator. For neutrons, this threshold corresponds to approximately 600 keV of
143 neutron energy deposited on a proton [11].

144



145
146 *Fig. 1. Photograph of the experimental setup showing the two EJ-309 scintillation detectors on the table with the*
147 *associated shielding; a phantom block is visible at the bottom of the picture. The proton beam*
148 *direction is left-to-right.*

149

150 The neutron pulses were distinguished from the gamma-ray pulses using an offline charge-
151 integration method [12]. The raw detector pulses were integrated over two regions: the tail
152 region of the pulse and the total length of the pulse. The exact ranges of these "tail" and "total"
153 integrals were optimized for each detector. Scintillation states excited by neutron scattering are
154 longer lived than states excited by photon scattering. Consequently, detector pulses created by
155 neutron events have larger tail integrals for a given total integral. Fig. 2 shows the tail-integral
156 versus total-integral projection of the soft tissue irradiation, which is indicative of the other results
157 because the neutron and gamma-ray fields were all similar to one another. Despite the large
158 number of photons present in the measured data, the neutron region is clearly separated from
159 the photon region. A second-order discrimination line was fit between the two regions to
160 discriminate the neutron and photon pulses: for a given total integral, any pulse whose tail
161 integral falls above the discrimination line is called a neutron, and any pulse whose tail integral
162 falls below the discrimination line is called a photon.

163 Fig. 3 shows the resulting neutron pulse height distributions for the four phantom target
164 materials irradiated with 155-MeV and 200-MeV protons.

165

166
167
168




Fig. 2. Pulse shape discrimination results from a soft tissue phantom irradiated with 200-MeV protons; the color bar is logarithmic.




Fig. 3. Measured neutron pulse height distributions for three phantom target materials irradiated with
(a) 155-MeV and (b) 200-MeV protons.

169
170
171
172

173 3. MONTE CARLO MODELING

174 The MCNPX-PoliMi code was used to characterize the secondary neutrons produced during
175 proton irradiation of biologically equivalent phantom materials. The code has the ability to write
176 a collision-log file containing all information about the particle interactions inside of user-
177 specified detector cells. These data are used to calculate detector response using a module-
178 based post-processing algorithm [13]. The proton transport was performed using the ENDF
179 proton data libraries included with the MCNPX code [14].

180 The MCNPX-PoliMi model was used to simulate the proton irradiation experiment at the
181 LLUMC experimental beam line. The floor and walls in the experimental hall were neglected in
182 the model because they do not contribute significantly to measured quantities, and to increase

183 computational efficiency. Table I lists the isotopic composition of the three CIRS, Inc. phantoms.
184 Compact bone is the most-dense phantom material at 1.910 g/cm^3 , followed by trabecular bone
185 at 1.160 g/cm^3 and soft tissue at 1.055 g/cm^3 .

186


187 *Table I. The composition and density of the four CIRS, Inc. phantom materials used in the*
188 *measurements taken at Loma Linda University Medical Center. Material composition is*
189 *given in weight percent.*

	Soft Tissue 1.055 g/cm^3	Trabecular Bone 1.160 g/cm^3	Compact Bone 1.910 g/cm^3
Hydrogen	8.47	6.99	3.30
Carbon	57.44	56.29	25.37
Nitrogen	1.65	2.03	0.91
Oxygen	24.59	22.72	35.28
Magnesium	7.62		3.36
Phosphorous		3.30	8.82
Chlorine	0.19	0.16	0.03
Calcium		8.49	22.91

190

191 The energy spectra of neutrons resulting from irradiation of the four CIRS, Inc. phantom
192 materials were simulated using MCNPX-PoliMi. Figs. 4 and 5 show the energy spectrum of
193 neutrons entering the front faces of the two detectors upon irradiation of the CIRS, Inc. phantoms
194 with 155 and 200 MeV protons, respectively. The shape of the neutron energy spectra is similar
195 between the different phantom materials, which is consistent with the measured detector
196 response shown in Fig. 3.

197




198

199

200

201

Fig. 4. The MCNPX-PoliMi simulated spectrum of neutrons entering the detectors during
irradiation of the CIRS, Inc. phantom materials with 155 MeV protons.



202
 203 *Fig. 5. The MCNPX-PoliMi simulated spectrum of neutrons entering the detectors during*
 204 *irradiation of the CIRS, Inc. phantom materials with 200 MeV protons.*

205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216

Table II lists the integral sum of the neutron energy spectra for all CIRS, Inc. phantom materials, the resulting value being the total number of neutrons entering the detectors upon irradiation of the phantom material with 155 or 200 MeV protons. The neutron detector fluence was greater when phantom materials were irradiated with 200 MeV protons compared to 155 MeV. The fluence of neutrons on the detectors was related to the density of the phantom material, with higher neutron fluence produced from denser phantom materials.

Table II. MCNPX-PoliMi simulated fluences of neutrons incident on the front faces of the two detectors for the different CIRS, Inc. phantom materials. Results are given as a ratio of neutrons incident on the front face of the detectors to the number of protons incident on the phantom.

Phantom Material	Incident Proton Energy (MeV)	Neutrons Incident on Detector Front Face per Incident Proton
Soft Tissue	155	1.22e-4
	200	1.92e-4
Trabecular Bone	155	1.23e-4
	200	1.95e-4
Compact Bone	155	1.50e-4
	200	2.40e-4


217
 218
 219
 220
 221
 222

Fig. 6 shows the proton- and neutron-flux distributions resulting from 155- and 200-MeV protons, interacting with a soft tissue phantom; Fig. 7 shows the flux distributions for the 200-MeV irradiation. These distributions were tallied in the 1-cm thick plane with respect to the center of the beamline. The proton distribution appears asymmetric because the beam was incident near the edge of the target phantom; protons that enter the air have a longer range than those

223 transporting purely through the phantom. The proton flux distributions clearly show the Bragg
224 peak at approximately 16 cm depth for 155 MeV and 25 cm depth for 200 MeV. The secondary
225 neutrons appear as an isotropic-like source emitted from the target along the path of the beam.
226 While the high energy neutrons are certainly forward-directed, the low energy neutrons are more
227 isotropic; additionally, the scattering in the phantom will also create an isotropic distribution.


228 Proton range and depth-dose characteristics within the phantom materials were also
229 evaluated using MCNPX-PoliMi; the results are shown for the CIRS, Inc. soft tissue phantom in
230 Fig. 8. The dose deposited by protons was tallied in volumetric slices of the phantom using an
231 MCNPX energy deposition tally. The resulting distribution matches the Bragg peak shape, as
232 anticipated. The occurrence of the Bragg peak just beyond the sharp drop in proton fluence is
233 expected as a majority of a proton dose is deposited at the end of its path.

234




235
236 Fig. 6. MCNPX-PoliMi results show the proton (left) and neutron (right) flux distributions from 155-
237 MeV protons interacting in a soft tissue phantom; the units are protons (or neutrons) per cm² per
238 source proton.

239



240
241 Fig. 7. MCNPX-PoliMi results show the proton (left) and neutron (right) flux distributions from 200-
242 MeV protons interacting in a soft tissue phantom; the units are protons (or neutrons) per cm² per
243 source proton.

244



245
 246 Fig. 8. The MCNPX-PoliMi simulated proton dose (solid lines) and fluence (dotted lines)
 247 as a function of depth in the CIRS, Inc. soft tissue phantom upon irradiation with 155 MeV (blue)
 248 and 200 MeV (red) protons.
 249

250 The simulated ranges of protons in the four CIRS, Inc. phantom materials were compared to
 251 the continuous-slowing down approximation (CSDA) range calculated using the Bragg-Kleeman
 252 rule, given in Eq. (1):
 253

$$R_T = R_{\text{ref}} \sqrt{\frac{A_T}{A_{\text{ref}}}}, \quad (1)$$

254 where R_T is the CSDA range of a proton at a given energy into a composite material T in units of
 255 g/cm^2 , R_{ref} is the known CSDA range in g/cm^2 of a proton with the same energy into a reference
 256 material, A_T and A_{ref} are the effective atomic numbers of the composite material T and the
 257 reference material, respectively. These values are calculated using Eq. (2):
 258

$$\sqrt{A_T} = \left(\sum_i \frac{W_i}{\sqrt{A_i}} \right)^{-1}, \quad (2)$$

260 where W_i is the mass fraction of the i^{th} element within the composite material and A_i is the atomic
 261 number of that i^{th} element [15].
 262

263 Table III gives the required quantities for calculation of proton CSDA ranges in the four CIRS,
 264 Inc. materials. Reference materials were selected from those available in the National Institute of
 265 Standards and Technology (NIST) PSTAR database; selection was based on compositional
 266 similarity to the CIRS, Inc. phantom materials. The ICRU compact bone was chosen as the
 267 reference material for CIRS, Inc. compact bone, A-150 tissue equivalent plastic as the reference
 268 material for CIRS, Inc. soft tissue and CIRS, Inc. trabecular bone, and finally polymethyl
 269 methacrylate (PMMA) for CIRS, Inc. plastic water. Along with compositional data, CSDA ranges
 270 of reference materials were gathered from the NIST PSTAR database [16].

271 Table IV gives the CSDA ranges of the CIRS, Inc. phantom materials calculated using Eq. (2)
 272 along with the ranges simulated using MCNPX-PoliMi. Comparison gave good agreement
 273 between the calculated and simulated ranges despite the differences in atomic composition
 274 between CIRS, Inc. Materials and the reference materials. The largest discrepancy occurred
 275 between the calculated and simulated values in trabecular bone, likely due to the lack of
 276 materials in the NIST PSTAR database that had composition and density similar to those of the
 277 CIRS, Inc. trabecular bone phantom.

278
 279 *Table III. Material densities, effective atomic numbers, and CSDA ranges of 155- and 200-MeV*
 280 *protons in NIST reference materials.*

Reference Material	Density (g/cm ³)	Effective Atomic Number	CSDA Range (g/cm ²)	
			155 MeV	200 MeV
A-150 Tissue Equivalent Plastic	1.127	4.73	16.56	25.75
Polymethyl Methacrylate	1.190	5.20	17.14	26.64
ICRU Compact Bone	1.850	6.76	17.94	27.86

281
 282 *Table IV. The CSDA ranges of protons in the four CIRS, Inc. phantom materials with incident energy*
 283 *E_p were calculated with the Bragg-Kleeman scaling rule given in Eq. (1). Reference materials were*
 284 *taken from those available in the NIST PSTAR database. The calculated CSDA range is compared*
 285 *to the proton range simulated by MCNPX-PoliMi.*


CIRS Material	Incident Proton Energy (MeV)	CSDA Range (g/cm ²)		
		Calculated	Simulated	%Difference
Soft Tissue	155	17.50	17.68	1.0%
	200	27.22	27.30	0.3%
Trabecular Bone	155	18.31	17.59	4.0%
	200	28.48	27.65	2.9%
Compact Bone	155	19.80	19.42	1.9%
	200	30.75	30.24	1.7%

286 Figs. 9 and 10 show the MCNPX-PoliMi simulated fluence map of neutrons within different


287 energy groups upon irradiation of the CIRS, Inc. soft tissue phantom with 155 and 200 MeV
 288 protons, respectively. Secondary neutrons between 0 and 5 MeV are emitted isotropically, while
 289 those above 5 MeV are more forward directed. Thus, the secondary neutron field can be
 290 separated into two distinct components; the isotropic, low-energy component and the forward-
 291 directed, high-energy component.

292 The biological effectiveness of neutron radiation peaks at energies of 1 MeV [17], suggesting
 293 that the majority of the biologically weighted dose from secondary neutrons arises from the low-
 294 energy component of the secondary neutron field. It is evident from Figs 9 and 10 that this dose
 295 will primarily be deposited within the patient.

296



297
 298 Fig. 9. MCNPX-PoliMi simulation of the fluence of neutrons with energy E_n resulting from the CIRS
 299 soft tissue phantom irradiated with 155 MeV protons, given in neutrons per cm^2 per incident proton.



300
 301 Fig. 10. MCNPX-PoliMi simulation of the fluence of neutrons with energy E_n resulting from the CIRS,
 302 Inc. soft tissue phantom irradiated with 200 MeV protons, given in neutrons per cm^2 per incident
 303 proton.

304

305 4. COMPARISON OF MEASURED AND SIMULATED DATA

306 Tallies in the standard MCNP code calculate average energy deposition with linear response
 307 functions; however, the response of organic scintillators is nonlinear and depends on the exact
 308 details of the neutron collision history in the detector [18]. The response of the EJ-309 scintillators
 309 was calculated using the MPPost code [19], which is a detection post-processor distributed with
 310 the MCNPX-PoliMi code. Fig. 11 shows the total simulated and measured neutron pulse height

311 distribution from the EJ-309 scintillators. One should note that the measured distributions were
 312 arbitrarily scaled because the absolute proton fluence was not monitored during the experiment.
 313




Fig. 11. MCNPX-PoliMi simulated and measured neutron pulse height distributions (PHDs) from 155- and 200-MeV irradiation of the CIRS, Inc. phantom materials (a) soft tissue; (b) trabecular bone; (c) and compact bone phantoms. Measured PHDs were arbitrarily scaled for comparison.

The pulse height distributions from the detectors can be converted into dose rate by inverting the known detector response functions [20]. The detector response functions have been measured and previously published in [11]. The energy deposited in the detector is converted

323 to dose deposited (in Gray) by dividing by the mass of each detector cell. This dose is then
324 converted to dose equivalent with the ICRP-21 energy-dependent radiation weighting factors
325 [17]. Table V summarizes the dose rates for each of the phantom materials and proton beam
326 energies. For comparison, MCNPX [14] point-detectors tallies with an ICRP-21 dose modifier are
327 used to calculate neutron dose equivalent directly from simulated protons; for these calculations,
328 all neutrons above the detection threshold were tallies. As expected, the dose rates unfolded
329 from the detector response slightly under-predict the MCNPX calculations due to the limited
330 sensitivity of our detection system to high energy neutrons. These results show that the neutron
331 dose rates at the detector position will reach significant levels at expected proton clinical
332 intensities, which may be on the order of $10^{10} - 10^{11}$ per second.

333

334 *Table V. Dose rates at the detector positions calculated using a MCNP point detector tally as well*
335 *as deconvolved from the simulated pulse height distributions. Units are mrem per hour per incident*
336 *proton rate (s⁻¹).*

Phantom Material	Energy (MeV)	Unfolded Detector Response	MCNPX Point Detector Tally
Soft Tissue	155	1.58e-7	2.71e-7
	200	2.41e-7	4.62e-7
Trabecular Bone	155	1.66e-7	2.66e-7
	200	2.52e-7	4.58e-7
Compact Bone	155	2.17e-7	3.10e-7
	200	3.27e-7	5.37e-7

337


338 5. SUMMARY AND DISCUSSION

339 Organic scintillators detect incident fast neutrons primarily through elastic scattering on
340 hydrogen nuclei: neutrons with energy less than a few hundred keV cannot deposit sufficient
341 energy to create a detectable pulse. For the experimental configuration considered in this work,
342 approximately 37% of neutrons incident on the detectors have energy below 600 keV and thus
343 cannot be detected. This energy spectrum is related to the detector placement relative to the
344 target block and self-attenuation of the neutrons within the target block, as well as neutron
345 scattered through the sides and back of the detector assembly. We are currently investigating
346 analysis techniques to enable data acquisition at lower detection thresholds, down to
347 approximately 100 keV. A thermal detection medium such as ^6Li glass could be incorporated into
348 the detection system to increase sensitivity to lower energy neutrons.

349 The neutrons produced by such high energy protons will also be quite high in energy; in fact,
350 they can take any energy up to the initial proton energy; approximately 6% of the neutrons
351 incident on the detector are above 20 MeV. Because the elastic scattering cross section
352 decreases as neutron energy increases, it is important to investigate the overall detection
353 efficiency of the high-energy neutrons. Fig. 12 shows the simulated energy spectrum of the

354 neutrons incident on the detector face for 200-MeV proton irradiation of the soft tissue target,
355 as well the portion of this incident spectrum that is detected. As expected, the detection
356 efficiency decreases as the incident neutron energy increases; Fig. 12b shows the energy-
357 dependent intrinsic neutron detection efficiency. The error bars on the plot are only statistical;
358 uncertainties in the nuclear data, particularly at high energies could contribute to the observed
359 fluctuations. The overall intrinsic detection efficiency is approximately 15%; however, if one
360 considers only the portion of the incident spectrum that is above the detection threshold, the
361 intrinsic efficiency is approximately 22%. Furthermore, the radiation weighting factor peaks near
362 1 MeV, and begins to quickly decrease for higher energies.

363



364
365 *Fig. 12. a. Simulated energy spectrum of incident and detected neutrons for 200-MeV proton irradiation of
366 the soft tissue target; b. energy dependent neutron detection efficiency.*

367

368 6. CONCLUSIONS

369 We have demonstrated a method of monitoring the neutron component of the secondary
370 radiation field produced by therapeutic protons. The method relies on direct detection of
371 secondary neutrons and gamma rays using organic scintillation detectors. These detectors are
372 sensitive over the full range of biologically relevant neutron energies above 0.5 MeV and allow
373 effective discrimination between neutron and photon dose.

374 An experiment was performed at the Loma Linda University Medical Center proton therapy
375 research beam line and corresponding models were created using the MCNPX-PoliMi code. Our
376 analysis showed agreement between the shape of the simulated and measured detector
377 response. Once fully validated, simulated detector response can be used to assess neutron dose
378 on a particular beam line without the need for experiments. Because the detector system is
379 portable and sensitive to neutrons and gamma rays, the described system could be used in the
380 future to evaluate secondary doses on various clinical beam lines for commissioning and
381 prospective data collection in pediatric patients treated with proton therapy. Future work will
382 focus on absolute validation of the simulation models as well as deconvolving the detector

383 response to produce absolute dose rate measurements for neutrons, as well as photons in a
384 single instrument.

385

386 ACKNOWLEDGMENTS

387 This work was funded in part by the ANDANTE grant from the Project 7 Framework of the
388 European Union.

389 The authors would like to thank Vladimir Varchena from CIRS Inc. for providing the phantom
390 material compositions and the target slabs used in the measurement. We would like to thank the
391 proton accelerator operator staff at Loma Linda University Medical Center for their support
392 before during the experimental run.

393 The authors have no relevant conflicts of interest to disclose.

394

395 REFERENCES

- 396 1. S. Garwicz, et al. "Second malignant neoplasms after cancer in childhood and
397 adolescence: a population-based case-control study in the 5 nordic countries." The
398 Nordic Society for Pediatric Hematology and Oncology The Association of the Nordic
399 Cancer Registries. *Int J Cancer.* 2000; 88:672–8.
- 400 2. W. Dorr, T. Herrmann, "Second primary tumors after radiotherapy for malignancies,
401 treatment-related parameters." *Strahlenther Onkol.* 2002; 178:357–62.
- 402 3. Paganetti, Harald, ed. *Proton Therapy Physics.* Boca Raton, FL: CRC/Taylor & Francis,
403 2012. Print. Ser. in Medical Physics and Biomedical Engineering.
- 404 4. J. Farah, V. Mares, M. Romero-Expósito, S. Trinkl, C. Domingo, V. Dufek (2015),
405 "Measurement of Stray Radiation Within a Scanning Proton Therapy Facility: EURADOS
406 WG9 Intercomparison Exercise of Active Dosimetry Systems", *Med. Phys.* 42, 2572 –
407 2583.
- 408 5. C. Lee, J. L. Williams, C. Lee, and W. E. Bolch (2005). "The UF Series of Tomographic
409 Computational Phantoms of Pediatric Patients". *Med. Phys.* 32, 3537 – 3548.
- 410 6. C. Z. Jarlskog, C. Lee, W. E. Bolch, X. G. Xu and H. Paganetti (2008). "Assessment of
411 Organ-Specific Neutron Equivalent Doses in Proton Therapy Using Computational
412 Whole-Body Age-Dependent Voxel Phantoms". *Phys. Med. Biol.* 53, 693 – 717.
- 413 7. B. S. Athar and H. Paganetti (2009). "Neutron Equivalent Doses and Associated Lifetime
414 Cancer Incidence Risks for Head & Neck and Spinal Proton Therapy". *Phys. Med. Biol.*
415 54, 4907 – 4926.
- 416 8. W. D. Newhauser, J. D Fontenot, A. Mahajan, D. Kornguth, M. Stovall, Y. Zheng, et al.
417 (2009). "The Risk of Developing a Second Cancer After Receiving Craniospinal Proton
418 Irradiation". *Phys. Med. Biol.* 54, 2277 – 2291.
- 419 9. P. J. Taddei, D. Mirkovic, J. D. Fontenot, A. Giebel, Y. Zheng, D. Kornguth, et al. (2009).

420 "Stray Radiation Dose and Second Cancer Risk for a Pediatric Patient Receiving
421 Craniospinal Irradiation with Proton Beams". *Phys. Med. Biol.* 54, 2259 – 2275.

422 10. Eljen Technologies, "EJ-309 Liquid Scintillator". <http://www.eljentechnology.com/index.php/products/liquid-scintillators/73-ej-309> (Accessed Jun. 18, 2015).

423 11. A. Enqvist, C. C. Lawrence, B. M. Wieger, S. A. Pozzi, T. N. Massey (2013), "Neutron Light
424 Output Response and Resolution Functions in EJ-309 Liquid Scintillation Detectors",
425 *Nucl. Instr. Meth. A* 715 p. 79.

426 12. M. Flaska, M. Faisal, D. D. Wentzloff, and S. A. Pozzi, "Influence of sampling properties
427 of fast-waveform digitizers on neutron–gamma-ray, pulse-shape discrimination for
428 organic scintillation detectors," *Nuclear Instruments and Methods in Physics Research*
429 Section A, vol. 729, pp. 456–462, 2013.

430 13. S. A. Pozzi, S. D. Clarke, W. Walsh, E. C. Miller, J. Dolan, M. Flaska, B. M. Wieger, A.
431 Enqvist, E. Padovani, J. K. Mattingly, D. Chichester, and P. Peerani, "MCNPX-PoliMi for
432 Nuclear Nonproliferation Applications," *Nucl. Instr. Meth. A* 694 (2012): 119 – 125.

433 14. D. B. Pelowitz, ed. MCNPX Manual, Version 2.7.0. LA-CP-11-00438, April 2011.

434 15. Knoll, Glenn F. "Radiation Interactions." *Radiation Detection and Measurement*. 4th ed.
435 Hoboken, NJ: John Wiley, 2010. 38-41.

436 16. Berger, M.J., Coursey, J.S., Zucker, M.A., and Chang, J. (2005), ESTAR, PSTAR, and
437 ASTAR: Computer Programs for Calculating Stopping-Power and Range Tables for
438 Electrons, Protons, and Helium Ions (version 1.2.3). Available:
439 <http://physics.nist.gov/Star>. National Institute of Standards and Technology,
440 Gaithersburg, MD.

441 17. ICRP Committee 3 Task Group, P. Grande and M. C. O'Riordan, chairmen, "Data for
442 Protection Against Ionizing Radiation from External Sources: Supplement to ICRP
443 Publication 15," ICRP-21, International Commission on Radiological Protection,
444 Pergamon Press (April 1971).

445 18. S. A. Pozzi, M. Flaska, A. Enqvist, and I. Paszit. "Monte Carlo and analytical models of
446 neutron detection with organic scintillation detectors," *Nucl. Instr. Meth A* 582 (2007):
447 629 – 637.

448 19. E. C. Miller, S. D. Clarke, M. Flaska, S. A. Pozzi, and E. Padovani (2011). "MCNPX-
449 PoliMiPost-Processing Algorithm for Detector Response Simulations". *Journal of Nuclear*
450 *Materials Management*, Vol. XL, No. 2, 34 – 41.

451 20. C A Miller, S D Clarke and S A Pozzi, "WE-AB-BRB-11: Portable Fast Neutron and Photon
452 Dose Meter." *Med. Phys.* 42, 3652 (2015).